Abstract
ObjectivesCOMMANDER-HF was a randomised trial comparing rivaroxaban 2.5 mg two times a day to placebo, in addition to antiplatelet therapy, in patients hospitalised for worsening heart failure with coronary artery...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have